98%
921
2 minutes
20
The diagnostic odyssey for people living with rare diseases (PLWRD) is often prolonged for myriad reasons including an initial failure to consider rare disease and challenges to systemically and systematically identifying and tracking undiagnosed diseases across the diagnostic journey. This often results in isolation, uncertainty, a delay to targeted treatments and increase in risk of complications with significant consequences for patient and family wellbeing. This article aims to highlight key time points to consider a rare disease diagnosis along with elements to consider in the potential operational classification for undiagnosed rare diseases during the diagnostic odyssey. We discuss the need to create a coding framework that traverses all stages of the diagnostic odyssey for PLWRD along with the potential benefits this will have to PLWRD and the wider community.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646190 | PMC |
http://dx.doi.org/10.3389/fped.2023.1283880 | DOI Listing |
J Craniofac Surg
September 2025
Hôpitaux Universitaires de Strasbourg (HUS), Pôle de Médecine et Chirurgie Bucco-dentaires, Hôpital Civil, Centre de référence des maladies rares orales et dentaires, CRMR O-Rares, Filire Santé Maladies rares TETECOU, European Reference Network ERN CRANIO, Strasbourg, France.
Amelogenesis imperfecta is a heterogeneous group of >100 different rare diseases. Affected individuals and families are facing diagnostic uncertainty and wandering and a therapeutic odyssey. Continuous multidisciplinary management from childhood to adulthood is essential, emphasizing the critical role of health care professionals.
View Article and Find Full Text PDFEur Heart J Qual Care Clin Outcomes
September 2025
BHF Centre for Cardiovascular Science, University of Edinburgh, Chancellor's Building, Edinburgh EH16 4SU, United Kingdom.
Aims: Type 2 myocardial infarction due to myocardial oxygen supply-demand imbalance is associated with poor outcomes. There are no guidelines to inform care for these patients. The consensus on the assessment and management of type 2 myocardial infarction is gained.
View Article and Find Full Text PDFSupport Care Cancer
August 2025
Department of Gynecology and Obstetrics, Ribeirao Preto Medical School, University of Sao Paulo, Av. Bandeirantes, Ribeirão Preto, 3900, Brazil.
Purpose: This qualitative inquiry delves into the diagnostic odyssey experienced by women diagnosed with locally advanced cervical cancer, seeking to elucidate the multifaceted factors influencing symptom recognition and access to healthcare services.
Methods: Semi structured interviews were conducted with 17 women diagnosed with locally advanced cervical cancer at a tertiary care hospital. The study employs Braun and Clarke thematic analysis, a structured approach to identifying, interpreting, and displaying themes that reflect participants' experiences.
Nat Commun
August 2025
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
VCP/p97 regulates a wide range of cellular processes, including post-mitotic Golgi reassembly. In this context, VCP is assisted by p47, an adapter protein, and VCPIP1, a deubiquitylase (DUB). However, how they organize into a functional ternary complex to promote Golgi assembly remains unknown.
View Article and Find Full Text PDFJ Am Coll Cardiol
August 2025
Department of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Background: Symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM) lacks approved therapies. The ODYSSEY-HCM trial (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy; NCT05582395), the largest to date in HCM patients, evaluating the efficacy of mavacamten in symptomatic adults with nHCM, did not demonstrate improvements in its primary endpoints (functional capacity and patient-reported health status).
Objectives: This exploratory analysis of the phase 3, randomized, placebo-controlled trial evaluated echocardiographic changes in nHCM patients from baseline to week 48.